ӳ��ý

Publications

An Immunomodulatory Peptide Confers Protection in an Experimental Candidemia Murine Model.

Freitas CG, Lima SMF, Freire MS, et al. An Immunomodulatory Peptide Confers Protection in an Experimental Candidemia Murine Model. Antimicrob Agents Chemother. 2017;61(8). doi:10.1128/AAC.02518-16

Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis.

Kuramoto N, Ohmura K, Ikari K, et al. Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis. Sci Rep. 2017;7(1):6911. doi:10.1038/s41598-017-07137-4

Control of immune-mediated pathology via the aryl hydrocarbon receptor.

Wheeler MA, Rothhammer V, Quintana FJ. Control of immune-mediated pathology via the aryl hydrocarbon receptor. J Biol Chem. 2017;292(30):12383-12389. doi:10.1074/jbc.R116.767723

Cerebrospinal fluid kynurenine and kynurenic acid concentrations are associated with coma duration and long-term neurocognitive impairment in Ugandan children with cerebral malaria.

Holmberg D, Franzén-Röhl E, Idro R, et al. Cerebrospinal fluid kynurenine and kynurenic acid concentrations are associated with coma duration and long-term neurocognitive impairment in Ugandan children with cerebral malaria. Malar J. 2017;16(1):303. doi:10.1186/s12936-017-1954-1

The skinny on obesity and cancer.

Sceneay J, McAllister SS. The skinny on obesity and cancer. Nat Cell Biol. 2017;19(8):887-888. doi:10.1038/ncb3583

IGF2 mRNA binding protein-2 is a tumor promoter that drives cancer proliferation through its client mRNAs IGF2 and HMGA1.

Dai N, Ji F, Wright J, Minichiello L, Sadreyev R, Avruch J. IGF2 mRNA binding protein-2 is a tumor promoter that drives cancer proliferation through its client mRNAs IGF2 and HMGA1. Elife. 2017;6. doi:10.7554/eLife.27155

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.

Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547(7664):453-457. doi:10.1038/nature23007

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.

Manguso RT, Pope HW, Zimmer MD, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547(7664):413-418. doi:10.1038/nature23270

Defining a Cancer Dependency Map.

Tsherniak A, Vazquez F, Montgomery PG, et al. Defining a Cancer Dependency Map. Cell. 2017;170(3):564-576.e16. doi:10.1016/j.cell.2017.06.010

ReMixT: clone-specific genomic structure estimation in cancer.

McPherson AW, Roth A, Ha G, et al. ReMixT: clone-specific genomic structure estimation in cancer. Genome Biol. 2017;18(1):140. doi:10.1186/s13059-017-1267-2